The FDA will pace up the overview of AC699, a novel therapy for sufferers with ER-positive, HER2-negative ESR1-mutant superior or metastatic breast most...
A panel of consultants on power myeloid leukemia focus on frequent affected person issues, adversarial impact concerns, and greatest practices for setting clear...
Sufferers 60 years and older with AML might profit from receiving lower-intensity remedy with decitabine. Decrease-intensity remedy with decitabine chemotherapy could also be...
